Prostate Cancer with Metastasis to the Omentum and Massive Ascites: A Rare Manifestation of a Common Disease

Zagouri, Flora; Papaefthimiou, Maria; Chalazonitis, Athanasios; Antoniou, Nikolaos; Dimopoulos, Meletios Α.; Bamias, Aristotle

doi:10.1159/000255336

Cited by 23 publications

(18 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…First, there are only four reported cases in the literature of pCa with omentum as its only metastasis 2, 3, 4, 5. None of the previously reported cases have the frequent imaging and staging of our case.…”

Section: Discussionmentioning

confidence: 76%

Isolated Non-ascitic Peritoneal Carcinomatosis from Metastatic Prostate Cancer

Sheng

Findley

Sadeghi‐Nejad

2017

Urology Case Reports

View full text Add to dashboard Cite

Prostate cancer most commonly metastasizes to bone, lung and liver. Omental metastasis of prostate cancer is extremely rare, with only a few cases reported in the literature, many of which have associated ascites. We present a case of non-ascitic omental metastasis of prostate cancer without any bone metastases. Furthermore, this patient has had two negative measurements of circulating tumor cells (CTCs) in the blood, suggesting a non-hematogenous route of metastasis to the omentum.

show abstract

Section: Discussionmentioning

confidence: 76%

Isolated Non-ascitic Peritoneal Carcinomatosis from Metastatic Prostate Cancer

Sheng

Findley

Sadeghi‐Nejad

2017

Urology Case Reports

View full text Add to dashboard Cite

show abstract

“…To the best of our knowledge, this is the largest series described to date since only 10 cases have been previously reported as isolated case reports [8,9,10,11,12,13,14,15,16,17] (table 1). …”

Section: Discussionmentioning

confidence: 99%

“…Other rare metastatic sites also described include the skin, central nervous system, eyes, parotid glands, testis, adrenal glands and the penis [4,5,6,7]. To our knowledge, prostate cancer with peritoneal metastases is an extremely rare entity with only 10 isolated cases reported in the literature [8,9,10,11,12,13,14,15,16,17] (table 1). …”

Section: Introductionmentioning

confidence: 99%

Castrate-Resistant Prostate Cancer with Peritoneal Metastases Treated with Docetaxel-Based Chemotherapy

Rizk

Danse²,

Aydın³

et al. 2013

Urol Int

View full text Add to dashboard Cite

Introduction: To identify the risk factors, characteristics and prognosis of patients treated with docetaxel-based chemotherapy for peritoneal carcinomatosis due to metastatic castrate-resistant prostate cancer (mCRPC). Methods: We retrospectively reviewed our series of mCRPC patients with peritoneal metastases treated with docetaxel-based chemotherapy between 2004 and 2010. Results: Six patients were identified from our institutions' internal cancer registry. Three out of these patients had been treated with laparoscopic radical prostatectomy (LRP). In addition to peritoneal metastases, other metastatic sites were mainly visceral. Only 1 patient developed bone metastases. Peritoneal carcinomatosis occurred mainly in patients with a high Gleason (= or >6) score since 5 out of our 6 patients had a Gleason score ≥7. All 6 patients were treated with docetaxel-based chemotherapy when they developed castration resistance. Five patients benefitted from chemotherapy according to their PSA or RECIST responses. Median survival from the start of docetaxel was 24.5 months. Conclusions: Our retrospective analysis suggests that peritoneal carcinomatosis occurs mainly in patients with a high Gleason score. It is also possible that tumor seeding occurs during LRP. Patients with peritoneal carcinomatosis resistant to castration seem to benefit from docetaxel-based chemotherapy.

show abstract

“…Recent reports of prostate cancer metastasizing to the stomach, peritoneum, pancreas and rectum [16][17][18][19] should increase the awareness of clinicians and radiologists that prostate cancer can present with metastases in atypical GI sites, contributing to an early detection, an accurate diagnosis and when feasible, appropriate management. Although the GIm-related symptoms are often being related to anticancer treatments, GI metastases from prostate cancer should be considered in the differential diagnosis, in order to early detect GI metastases at the time of the first occurrence of gastrointestinal symptoms, mainly in the future where the life expectancy of the patients affected by prostate cancer could be further prolonged by the availability of new active drugs also in early phases of the disease.…”

Section: Future Perspectivementioning

confidence: 99%

Unusual small bowel metastatic localization in a castration-resistant prostate cancer patient

Maines¹,

Caffo²,

Veccia³

et al. 2014

Clinical Practice

View full text Add to dashboard Cite

Practice points• The availability of active new drugs has changed the natural history of advanced castration-resistant prostate cancer, significantly improving overall survival and thus leading to an increased risk of observing metastases in atypical sites. • Bone and lymph nodes are usually the most frequent sites for distant metastases arising from prostate cancer. Visceral metastases are rare and when they occur, they usually involve the liver and lungs. • The gastrointestinal (GI) tract is usually directly invaded from adjacent organs or enlarged lymph nodes. Hematogenous or lymphatic spread from prostate cancer to GI tube is uncommon, but the incidence seems to be increasing. • The presenting symptoms of GI metastases, such as nausea, vomiting and abdominal pain and body weight loss are usually nonspecific, and all of them are often related to anticancer treatments or progressive disease. • In patients with a history of prostate cancer and new-onset GI symptoms, GI metastases should be considered in the differential diagnosis.The introduction of docetaxel into clinical practice and the more recent availability of other active therapeutic options, such as cabazitaxel, abiraterone acetate, enzalutamide and radium-223, have significantly improved the clinical outcomes of patients affected by castration-resistant prostate cancer (CRPC). Bone and nodes metastases are usually the first presentation of advanced disease, but the improvement in overall survival and the greater use of imaging techniques for restaging of metastatic CRPC patients have led to a previously unexpected clinical scenario characterized by an increased incidence of visceral metastases not only in the liver and lungs, but also in atypical sites such as the brain or gastrointestinal tract. We describe a rare case of CRPC metastasizing to the small bowel with particular endoscopic and radiographic findings.

show abstract

Prostate Cancer with Metastasis to the Omentum and Massive Ascites: A Rare Manifestation of a Common Disease

Cited by 23 publications

References 9 publications

Isolated Non-ascitic Peritoneal Carcinomatosis from Metastatic Prostate Cancer

Isolated Non-ascitic Peritoneal Carcinomatosis from Metastatic Prostate Cancer

Castrate-Resistant Prostate Cancer with Peritoneal Metastases Treated with Docetaxel-Based Chemotherapy

Unusual small bowel metastatic localization in a castration-resistant prostate cancer patient

Contact Info

Product

Resources

About